Aclasta 5mg/100 ml Solution for Infusion

Manufacturer
FRESENIUS KABI AUSTRIA GMBH(AUSTRIA)

Registraction Number
MAL19126016ACRZ

Content:

• Active Ingredient: Zoledronic acid 5mg per 100mL solution
• Inactive Ingredients: Mannitol, sodium citrate, and water for injections

• Osteoporosis: In postmenopausal women and men at increased risk of fracture, including those with a recent low-trauma hip fracture.
• Glucocorticoid-Induced Osteoporosis: To prevent bone mineral density loss and increase bone mineral density in postmenopausal women and men on long-term glucocorticoid therapy.
• Paget’s Disease of Bone: To treat the disease and manage symptoms.

• Osteoporosis: A single intravenous infusion of 5mg Aclasta once a year.
• Glucocorticoid-Induced Osteoporosis: A single intravenous infusion of 5mg Aclasta once a year.
• Paget’s Disease: A single intravenous infusion of 5mg Aclasta. Retreatment may be needed after one year or longer.